Company: WHWK
Filing Date: 2025-01-21
Form Type: PREM14A
Source: 0001193125-25-009599
Chunk: 841

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-01-21
Form: PREM14A
Chunk 841
---
eto as Schedule 9.6 with respect to this Agreement. [***]. Subject to
Aadi’s obligations under Sections 9.1 and 9.4, Aadi shall have the right to issue subsequent press releases or other public statements pertaining to the activities conducted hereunder. In any case, neither Party will be prevented from complying
with any duty of disclosure it may have pursuant to Applicable Laws or pursuant to the listing rules of any recognized stock exchange on which such Party’s securities are traded, subject to that Party notifying the other Party of such duty and
limiting such disclosure as reasonably requested by the other Party (unless such disclosure is necessary, in the reasonable opinion of the disclosing Party’s legal counsel, to comply with Applicable Laws or such listing rules) and giving the
other Party an opportunity to review and comment on any proposed disclosure. After release of a press release in accordance with this Section 9.6(a), each Party may further disclose to Third Parties the information contained in such press
release, without the prior written consent of the other Party.

(b) For avoidance of doubt, subject to this Article IX, Aadi shall
have the right to publicly disclose without WuXi Biologics’ prior written consent: (i) the achievement of any milestone under this Agreement; (ii) the commencement, completion, material data and key results of any Clinical Trial
conducted under this Agreement; and (iii) any information relating to the Development or Commercialization of Licensed Products in the Field in the Territory.

9.7 Prior Non-DisclosureAgreements. This Agreement supersedes the Prior CDA
regarding the subject matter of this Agreement. All information exchanged between the Parties under the Prior CDA shall be deemed to have been disclosed under this Agreement on a going-forward basis and shall be subject to the terms of this
ARTICLE IX as of the Effective Date.

ARTICLE X

INTELLECTUAL PROPERTY

10.1 Ownership of Inventions. [***].

10.2 Patent Prosecution and Maintenance.

(a) [***].

(b) [***].

(c) [***].

G-22

10.3 Patent Term Extensions. [***].

10.4 Enforcement.

(a) [***].

(i) [***].

(ii) [***].

(iii) [***].

(b) [***].

(i) [***].

(ii) [***].

(iii) [***].

(c) [***].

10.5 Third Party Infringement Claims. Each Party shall promptly